Form 8-K

8-K — Jasper Therapeutics, Inc.

Accession: 0001213900-26-056596

Filed: 2026-05-14

Period: 2026-05-14

CIK: 0001788028

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — ea0290792-8k_jasper.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED MAY 14, 2026 (ea029079201ex99-1.htm)

GRAPHIC (ea029079201_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0290792-8k_jasper.htm · Sequence: 1

false

0001788028

2026-05-14

0001788028

JSPR:VotingCommonStockParValue0.0001PerShareMember

2026-05-14

0001788028

JSPR:RedeemableWarrantsEachTenWarrantsExercisableForOneShareOfVotingCommonStockAtExercisePriceOf115.00Member

2026-05-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):

May 14, 2026

JASPER THERAPEUTICS, INC.

(Exact Name

of Registrant as Specified in its Charter)

Delaware

001-39138

84-2984849

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2200 Bridge Pkwy Suite #102

Redwood City, California 94065

(Address of Principal Executive Offices) (Zip

Code)

(650) 549-1400

Registrant’s telephone number, including

area code

N/A

(Former

Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

(Title

of each class)

(Trading

Symbol)

(Name

of exchange on which registered)

Voting Common Stock, par value $0.0001 per share

JSPR

The Nasdaq Stock Market LLC

Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00

JSPRW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 14, 2026, Jasper Therapeutics, Inc. issued a press release reporting

its financial results for the quarter ended March 31, 2026 and providing a corporate update. A copy of the press release is furnished

as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instructions B.2 of Form 8-K, the information

in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished under Item 2.02 and Item 9.01 of Current

Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended

(the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be deemed incorporated by reference

in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference

in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release, dated May 14, 2026.

104

Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 14, 2026

JASPER THERAPEUTICS, INC.

By:

/s/ Herb Cross

Name:

Herb Cross

Title:

Chief Financial Officer

EX-99.1 — PRESS RELEASE, DATED MAY 14, 2026

EX-99.1

Filename: ea029079201ex99-1.htm · Sequence: 2

Exhibit 99.1

Jasper Therapeutics Reports First Quarter 2026

Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE)

– Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab,

a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic

inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2026 and provided a corporate update.

“In recent months, we have continued to advance

the briquilimab development program in CSU.” said Jeet Mahal, President and Chief Executive Officer of Jasper. “Following our

positive clinical data update in January, we have conducted an analysis of the full data package from BEACON, SPOTLIGHT and the open-label

extension study to drive the selection of two active dosing regimens to evaluate in our Phase 2b study. In parallel we have also updated

and refiled the Phase 2b protocol with the FDA as we work to secure additional funding to enable commencement of the study in the second

half of this year as planned.”

Highlights for First Quarter 2025 and Recent Weeks

● Refiled an updated Phase 2b protocol with the

FDA for the planned Phase 2b study of briquilimab in CSU.

● Jeet

Mahal appointed as Chief Executive Officer to lead next phase of clinical growth.

● Reported positive updated data from briquilimab

studies in chronic spontaneous urticaria in January 2026:

o 67% of additional patients (n=6) enrolled in the BEACON study given an initial dose of 240mg briquilimab

followed by 180mg every 8 weeks achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points

o 75% of CSU participants (n=36) enrolled in the open label extension dosed with 180mg briquilimab every

8 weeks achieved a complete response or well controlled disease at 12 weeks

o With a median duration of follow up of more than 200 days on 63 participants in the open label extension

study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study

First Quarter Fiscal 2026 Financial Results

● Cash and cash equivalents as of March 31, 2026,

totaled $14.1 million.

● Research and development expense for the three

months ended March 31, 2026, was $5.8 million.

● General and administrative expense for the three

months ended March 31, 2026, was $5.1 million.

● Jasper reported a net loss of $1.2 million, or

basic and diluted net loss per share attributable to common stockholders of $0.04 for the three months ended March 31, 2026.

About Jasper

Jasper is a clinical-stage biotechnology company

focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal

antibody that blocks stem cell factor from binding to the KIT receptor, thereby inhibiting signaling through the receptor. This inhibition

disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of

the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently evaluating briquilimab

as a treatment in patients with CSU, CIndU and asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy

volunteers, with positive clinical outcomes in CSU, CIndU and allergic asthma. For more information, please visit us at www.jaspertx.com.

Forward-Looking Statements

Certain statements included in this press release that are not historical

facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation

Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,”

“estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,”

“would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,”

“outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical

matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, including

with respect to its potential in mast cell driven diseases such as CSU, CIndU and asthma; Jasper’s continued advancement of its

briquilimab development program in CSU; Jasper’s Phase 2b study in CSU, including the planned commencement thereof and the selection

of dosing regimes; and Jasper’s work to secure additional funding for its Phase 2b study in CSU. These statements are based on various

assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual

performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not

be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual

events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties,

including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may

not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that

clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk

that prior test, study and trial results may not be replicated in continuing or future studies and trials; Jasper’s ability to continue

as a going concern and its imminent need to raise additional funding to continue its operations; the risk that Jasper may be unable to

raise capital to continue its operations and its Phase 2b/3 study in CSU; the risk that Jasper will be unable to successfully market or

gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s

product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies

and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third

parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily;

the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected

by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection

for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated

from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025

and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual

results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking

statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should

not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue

reliance should not be placed upon the forward-looking statements.

Contacts:

Alex Gray (investors)

Jasper Therapeutics

650-549-1454

agray@jaspertx.com

Joyce Allaire (investors)

LifeSci Advisors

617-435-6602

jallaire@lifesciadvisors.com

Media:

media@jaspertx.com

JASPER THERAPEUTICS,

INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share data)

(unaudited)

Three Months Ended

March 31,

2026

2025

Operating expenses

Research and development(1)

$ 5,814

$ 16,157

General and administrative(1)

5,138

5,645

Total operating expenses

10,952

21,802

Loss from operations

(10,952 )

(21,802 )

Interest income

164

624

Change in fair value of warrant liability

9,640

—

Other expense, net

(26 )

(63 )

Total other income, net

9,778

561

Net loss and comprehensive loss

$ (1,174 )

$ (21,241 )

Net loss per share attributable to common stockholders, basic and diluted

$ (0.04 )

$ (1.41 )

Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted

28,671,819

15,022,122

(1) Amounts include non-cash stock based compensation expense

as follows (in thousands):

Three Months Ended

March 31

2026

2025

Research and development

$ 221

$ 571

General and administrative

$ 202

$ 1,240

Total

423

$ 1,811

JASPER THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

March 31,

2026

December 31,

2025

Assets

Current assets:

Cash and cash equivalents

$ 14,144

$ 28,692

Prepaid expenses and other current assets

6,148

5,953

Total current assets

20,292

34,645

Property and equipment, net

102

Operating lease right-of-use assets

317

502

Restricted cash

417

Other non-current assets

113

Total assets

$ 21,184

$ 35,779

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$ 2,439

$ 6,220

Current portion of operating lease liabilities

757

1,235

Accrued expenses and other current liabilities

5,800

5,745

Total current liabilities

8,996

13,200

Warrant liability

6,524

16,164

Other non-current liabilities

2,264

Total liabilities

17,784

31,628

Stockholders’ equity:

Preferred stock

—

Common stock

Additional paid-in capital

321,241

320,818

Accumulated deficit

(317,844 )

(316,670 )

Total stockholders’ equity

3,400

4,151

Total liabilities and stockholders’ equity

$ 21,184

$ 35,779

GRAPHIC

Filename: ea029079201_ex99-1img1.jpg · Sequence: 3

Binary file (23000 bytes)

Download ea029079201_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

May 14, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 14, 2026

Entity File Number

001-39138

Entity Registrant Name

JASPER THERAPEUTICS, INC.

Entity Central Index Key

0001788028

Entity Tax Identification Number

84-2984849

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2200 Bridge Pkwy Suite #102

Entity Address, City or Town

Redwood City

Entity Address, State or Province

Entity Address, Postal Zip Code

94065

City Area Code

650

Local Phone Number

549-1400

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Voting Common Stock, par value $0.0001 per share

Title of 12(b) Security

Voting Common Stock, par value $0.0001 per share

Trading Symbol

JSPR

Security Exchange Name

NASDAQ

Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00

Title of 12(b) Security

Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00

Trading Symbol

JSPRW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=JSPR_VotingCommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=JSPR_RedeemableWarrantsEachTenWarrantsExercisableForOneShareOfVotingCommonStockAtExercisePriceOf115.00Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type: